Constantine Tam

78PUBLICATIONS
317CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Language documentation and descriptionPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (78)

|Jul 13, 2026
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.

|Jul 07, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

|Jun 11, 2026
Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.

|Jan 31, 2026
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Mazyar Shadman, Asher Chanan-Khan, David Campbell

|Jan 08, 2026
First-line treatment for CLL in the era of targeted therapy.

Matthew S Davids, Stephan Stilgenbauer, Constantine S Tam

|Nov 18, 2025
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Richard T Maziarz, Michael R Bishop, Constantine S Tam

Pageof 13

Frequent Collaborators

17 joint publications

John Francis Seymour

13 joint publications

Stephen S Opat

9 joint publications

Judith Trotman

8 joint publications

Andrew W Roberts